In the absence of robust clinical trial data and treatments approved by regulatory authorities, treatment of HAE‐nC1 INH is based on clinical experience with the more common forms of HAE with C1 INH deficiency and with therapies that either directly or indirectly modulate bradykinin metabolism 4. This evidence concerns the gene SERPING1 and hereditary angioedema.